Experimental treatment options in absence epilepsy by Luijtelaar, E.L.J.M. van et al.






The following full text is a preprint version which may differ from the publisher's version.
 
 





Please be advised that this information was generated on 2020-09-10 and may be subject to
change.
Send Orders for Print-Reprints and e-prints to reprints@benthamscience.ae 
  Current Pharmaceutical Design, 2017, 23, 1-16 1 
REVIEW ARTICLE 
 1381-6128/17 $58.00+.00  © 2017 Bentham Science Publishers 
Experimental Treatment Options in Absence Epilepsy 
Gilles van Luijtelaar1,*, Mehrnoush Zobeiri2, Annika Lüttjohann2 and Antoine Depaulis3,4,5 
1Biological Psychology, Donders Centre for Cognition, Radboud University, Nijmegen, The Netherlands; 2Institute of Physiology I, 
Westfälische Wilhelms Universität, D-48149 Münster, Germany; 3Inserm, U1216, F-38000 Grenoble, France; 4Univ. Grenoble 
Alpes, Grenoble Institut des Neurosciences, F-38000 Grenoble, France; 5CHU de Grenoble, Hôpital Michallon, F-38000 Grenoble, 
France 
 
A R T I C L E  H I S T O R Y 
 
Received: June 20, 2017 





Abstract: Background: The benign character of absence epilepsy compared to other genetic generalized epilepsy 
syndromes has often hampered the search for new treatment options. Absence epilepsy is most often treated with 
ethosuximide or valproic acid. However, both drugs are not always well tolerated or fail, and seizure freedom for 
a larger proportion of patients remains to be achieved. The availability of genuine animal models of epilepsy does 
allow to search for new treatment options not only for absence epilepsy perse but also for other genetic - previ-
ously called idiopathic - forms of epilepsy. The recent discovery of a highly excitable cortical zone in these mod-
els is considered as a new therapeutic target area. 
Methods: Here, we provide an overview regarding the search for new therapeutical options as has been investi-
gated in the genetic rodent models (mainly WAG/Rij and GAERS) including drugs and whether antiepileptogene-
sis can be achieved, various types of electrical and optogenetical invasive stimulations, different types of non-
invasive stimulation and finally whether absence seizures can be predicted and prevented.  
Results: Many factors determine either the cortical and or thalamic excitability or the interaction between cortex 
and thalamus and offer new possibilities for new anti-absence drugs, among others metabotropic glutamatergic 
positive and negative allosteric modulators. The inhibition of epileptogenesis by various drugs with its wide-
spread consequences seems feasible, although its mechanisms remain obscure and seems different from the anti-
absence action. Surgical intervention on the cortical zone initiating seizures, either with radiosurgery using syn-
chrotron-generated microbeams, or ablation techniques might reduce spike-and-wave discharges in the rodent 
models. High frequency electrical subcortical or cortical stimulation might be a good way to abort ongoing spike-
and-wave discharges. In addition, possibilities for prevention with real-time EEG analyses in combination with 
electrical stimulation could also be a way to fully control these seizures.  
Conclusion: Although it is obvious that some of these treatment possibilities will not be used for absence epi-
lepsy and/or need to be further developed, all can be considered as proof of principle and provide clear directives 
for further developments.   
Keywords: ?????????????. 
1. INTRODUCTION  
 Absence Epilepsy (AE) is characterized by generalized non-
convulsive seizures concomitant with a cessation of bodily activity 
and associated with a transient alteration of consciousness and re-
sponsiveness. Seizures in patients are often accompanied by mild 
automatisms or moderate clonic components affecting the limbs, 
eyeballs or eyelids [1]. Typical absence seizures are accompanied 
bybilateral symmetrical, synchronous and regular 3-Hz spike-and-
wave discharges (SWDs) present on the electroencephalogram. 
Absence seizures start and end abruptly without any sign of postic-
tal depression. They first occur around the age of 4-6 years and 
preferentially occur during periods of quiet wakefulness, inattention 
and preferably at transitions between awakening and sleep. In gen-
eral, they last less than 10-20 sec but may occur frequently in some 
patients. The pharmacological sensitivity of absence seizures is 
quite unique: they are suppressed by ethosuximide (ETX), which is 
not effective in most other forms of epilepsy [2] but also by some 
large-spectrum antiepileptic drugs (mainly valproate (VPA) and, to 
a lesser extent lamotrigine (LTG)) [3]. By contrast, they are aggra-
vated by sodium channel blockers such as carbamazepine and 
phenytoin that are rather effective against generalized convulsive  
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and partial seizures [1]. AE patients generally do not present other 
neurological disorders, although cognitive and affective comorbid-
ities have been described [4]. In typical childhood absence epilepsy, 
remission is observed during adolescence in about 70% of the pa-
tients [5]. 
1.1. Genetic Rodent Modelsof Absence Epilepsy 
 Our current knowledge on AE has been mainly achieved from 
experiments performed onanimal models and more specifically, 
genetic models in mice and rats (see [6,7] for recent reviews). The 
genetic background of absence seizures in these modelsprovidesa 
unique opportunity for studyingindividuals with a natural history-
close to clinical situations; an ideal condition to understand the 
pathophysiology of human AE and its evolution over life time [6]. 
Different genetic models have been described in mice and rats 
based on EEG recordings demonstrating the occurrence of sponta-
neous SWDs associated with behavioural arrest. Three main fea-
tures confer to these models a considerable value in the understand-
ing of AE: (i) the possibility to record SWDs regularly, over a life-
time period, in either, and preferably, freely moving or, when nec-
essary, in immobilized animals; (ii) the comparison of data between 
epileptic and non-epileptic lines and, (iii) the possibility to explore 
epileptic animals before the onset of seizures. This is in particular 
the case in the two rat models which have been described and 
mostly studied: the WAG/Rij [8,9] and the GAERS [10,11] strains. 
The fully developed SWDs are present in all GAERS at 30 days 
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postnatal [12,13] and in 80% of the 3-month old WAG/Rij indi-
viduals [14], for a head to head comparison between WAG/Rij’s 
and GAERS rats see [15]. In all genetic models of AE, animals 
exhibit bilateral and synchronized SWDs that start and end abruptly 
[6]. As in human patients, there is no postictal depression. These 
SWDs have a frequency between 5-9 Hz and a duration of 1 to 60s 
in the mice and rat models. The recurrence of SWDs can vary from 
1 to 260 SWDs per hour, depending on the model, the age of the 
animals and the recording conditions. The spike frequency is gener-
ally higher at the beginning of a SWD (up to 11 Hz in rat models) 
whereas a frequency of about 7-9 Hz is observed one-two seconds 
after its beginning and for the rest of the discharge [10, 16-20]. This 
may reflect the dynamics in firingpattern of neurons underlying 
SWDs and suggests that different circuits may be rapidly recruited 
within the first few seconds of SWDs [21]. Similar frequency dy-
namics have been found in people with AE [20]. 
1.2. How Animal Models of Absence Epilepsy can Help Devel-
oping Innovative Therapeutic Strategies  
 The excellent pharmacological predictivity of the two rat mod-
els, as well as the steady occurrence of SWDs over extended peri-
ods of time, make them models of choice to develop and evaluate 
new and innovative therapies for the epilepsies[11]. These new 
treatment options are not developed for invasive treatment of AE 
per se, as this form of epilepsy remains relatively benign compared 
to other syndromes and because absence seizures are generally 
reasonably well controlled by several antiepileptic drugs (see later). 
However, the recent identification of a highly excitable cortical 
"focus" triggering and generating spontaneous SWDs [19,22] offers 
a novel opportunity to show proofs of concept for innovative tar-
geted strategies.  
 The initial work inWAG/Rijbased on cortico-cortical and cor-
tico-thalamic network analyses (non-linear association strength) 
strongly suggested that SWDs are initiated in the somatosensory 
cortex (SoCx) [23]. Since then, the initiating role of this cortical 
region was confirmed and further explored in WAG/Rij [24-
33],GAERS [19,34–38], Long-Evans rats with spontaneous occur-
ring SWDs [39,40] and in mice with a juvenile myoclonic epilepsy 
mutation (Gabra1[A322D]) exhibiting both absence and myoclonic 
generalized seizures [41]. Studying the association strength be-
tween field potentials recorded from cortical and thalamic regionsin 
freely moving GAERS also suggested the facial SoCx, or barrel 
cortex, as an origin for the initiation of SWDs [35]. In addition, 
short (1-2 sec) SWDs were recorded in this cortical area that did not 
spread to other regions, whereas the reverse was never observed 
[19]. These findings along with fMRI data and focal pharmacologi-
cal manipulations from the rodent models, demonstrated that 
‘SWDs are initiated in the facial SoCx and that an intracortical 
propagation of ictal activity appears as the mechanism of primary 
generalization of spontaneous occurring SWDs’ [22]. The concept 
of a cortical initiation zone for SWDs is in line with the outcomes 
of high density EEG and MEG  studies revealinga role of the fron-
tal cortex in initiation of SWDs in AE patients [42,43].The identifi-
cation of the SoCx as the site of SWDs initiation has allowed to 
start deciphering the cellular mechanisms underlyingSWDs in 
GAERSby in vivo intracellular electrophysiological recordings. It 
was shown for instance that the ‘occurrence of spike-wave activity 
on the surface EEG of SoCx is correlated withthe corresponding 
deep-layer pyramidal neurons which exhibit suprathreshold rhyth-
mic depolarizations’ with accompanying action potentials, super-
imposed on a tonic membrane hyperpolarization that lasts through-
out the SWD [19,36,37]. This increase in cell polarization observed 
in cortical neurons during SWDs differs from the classical sustained 
depolarizing shift found in other forms of seizures. Moreover, the 
‘mean firing rate of cortical neurons in GAERS during SWDs is not 
changed compared to the preceding quiescent periods, even in the 
ictogenic neurons. Cortical neurons during seizures may not sys-
tematically generate “paroxysmal” discharges and absence seizures 
may rather be associated with a change in the temporal pattern of 
neuronal firing [11]. 
 These findings support the hypothesis that ‘SWDs primarily 
originate from aberrant activity of pyramidal neurons located in the 
deep layers of SoCx. This activity associates an excessively depo-
larized membrane potential together with an elevated and highly 
regular spontaneous firing during interictal periods, with rhythmic 
brisk discharges during SWDs that precede and exceed the firing of 
distant cortical and thalamic neurons’. It may suggest that specific 
molecular alterations exist in cortical neurons [11]. For instance, in 
vitro experiments in the WAG/Rij suggest that dysregulation of 
hyperpolarization- activated current (Ih), the pacemaker current 
carried by hyperpolarization-activated cyclic nucleotide-gated po-
tassium channels (HCN), may promote epileptogenesis andstabi-
lizes the HCN channels function through compensatory mecha-
nisms. It may also be invoved in the termination of SWDs [44]. Its 
cortical origin, as well as the underlyingpathophysiological mecha-
nismsremain to be examined in other models of AE.  
2. NEW ANTI-ABSENCE DRUGS? 
 Little progress has been made regarding the development of 
new anti-absence drugs during the last 20 years. Indeed, the most 
prevalent anti-absence medications, ETX and VPA, have been used 
for the last 50-60 years and only LTG, which has been introduced 
in the 1990’s, is used currently on a relatively large scale as mono-
therapy. An open-label, randomized, parallel-group study compar-
ing head-to-head the efficacy of VPA and LTG in newly diagnosed 
children and adolescents with typical absence seizures during one 
year showed that the efficacy of VPA was superior after 1 months. 
At 3 and 12 months the differences were no longer significant, 
althoughmore patients taking VPA achieved seizure freedom than 
did those taking LTG [45]. Zonisamide (ZNS) approved for adjunc-
tive treatment of partial seizures in adults, has also been investi-
gated in a group of 45 children and adolescents with absence epi-
lepsy and about 49% of them became seizure free [46]. ZNS is not 
recommended due to its slow onset and chances of adverse effects 
and thatother antiabsence drugs have a better safety and efficacy 
profile. Theshort (2 weeks) term efficacy of levetiracetam (LEV) 
was established in a randomized double-blind parallel-
groupplacebo-controlled design. The outcomes showed that this 
compound was superior to placebo in suppressing absences [47]. 
However, the responder rates were modest.  
 The differences in efficacy among the three first-line anti-
absence drugs have become clear from a large randomized double 
blind multicenter clinical trial of initial therapy, aiming to compare 
different aspects of ETX, VPA and LTG.  ETX and VPA wereiden-
tified as drugs with superior efficacy compared to LTG. However, 
ETX  was identified asthe optimal initial therapy since it had fewer 
attentional adverse effects when compared to VPA [3,48]. The 
higher efficacy of ETX and VPA in comparison toLTG was con-
firmed by others [49], also as a second monotherapy [50]. Berg et 
al. (2014) proposed that ETX might have a disease-modifying ef-
fect and a high remission rate [5]. In addition, children who were 
succesfully treated with ETX as the first medication, had a particu-
lar low risk of developing subsequent generalized tonic clonic sei-
zures [51]. Despite these rather favorable outcomes for ETX, ther-
apy with this drug was found to fail in 47% of subjects due to sei-
zures, intolerable side-effects oreven withdrawal from the study [2]. 
Epidemiologic cohort studies showed only seizure freedom in the 
range from 21%–74%2. In five prospective cohort studies, the pro-
portion of seizure free subjects was 57%–74%. An Italian multi-
centre study showed that 49% of their cohort of drug resistant ab-
sence patients did not become seizure free even after 3 or 4 types of 
antiepileptic drugs during a 3-year follow up study[52]. Although 
‘AE is labeled as a “benign” syndrome, its clinical course is vari-
able and remission rates are far lower than in other classic benign 
genetic epilepsies such as Benign Rolandic Epilepsy’[2]. All this 
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implies that there is ample room for new and better anti-absence 
drugs that should be compared with the current optimal initial stan-
dard, ETX.  
 Interestingly, a better usage of the existing drugs can be made: 
afavorable drug response to ETX and VPA can be predicted with a 
high sensitivity and specificity. This prediction is based on spectral 
density of the peak frequency of the first 2 s of SWDs. Other fac-
tors that might have played a role in drug response in AE patients, 
such as type of drug, age of onset, type of syndrome (juvenile ab-
sence epilepsy or childhood AE) did not predict a favorable out-
come, although some of these factors might be underpowered [53]. 
A second way to predict favorable drug responses determined 16-20 
weeks after the initiation of treatment (ETX and LTG) is based on 
the identification of polymorphism of the T-type Ca2+ channel 
genes CACNA1G, CACNA1H, and CACNA1I, involved in the 
pathological absence networkand of the ABCB1 transporter gene 
which codes for P-glycoprotein, a drug efflux transporter [54]. It 
acts at the membrane of brain capillary endothelial cells and is rele-
vant for the action of LTG. It was found that the presence of either 
a CACNA1H or a CACNA1I missensevariant was more often asso-
ciated with lack of response to ETX and that an ABCB1 missense 
polymorphism was less, whereas two CACNA1H polymorphisms 
were more common in good responders to LTG. The authors con-
clude that “prospects are bright for integrated genetic/nonheritable 
precision medicine therapies for children with CAE [54]”. 
2.1. A Bag Full of Possibilities and Challenges 
 In principle,there is an unlimited number of ways to manipulate 
the occurrence of SWDs, among them the classical neurotransmit-
ters that modulate the activity of cortico-thalamo-cortical oscilla-
tions (C-T-C) (for recent reviews see [55-57]). Anti-inflammatory 
drugs might also be putative candidates as antiepileptic drugs [58], 
including absence epilepsy [59]. For example, the selective COX-2 
inhibitor etoricoxib, which inhibits the production of pro-
inflammatory prostaglandins, suppresses SWDs, although not to a 
large extent [60]. In addition, signaling pathways are getting more 
and more attention. In particular, it was shown that inhibition of 
themammalian target for rapamycin (mTOR), a regulator of differ-
ent cellular processes, reduced number and mean duration of SWDs 
when administered acutely or sub-chronically [61]. Also, ion chan-
nel modulators such as (-)BRL34915, an active isomer of a K+ 
channel opener, reduced SWDs in WAG/Rij rats [62]. Compounds 
thatselectively target the upregulated genes for channel Nav1.1 and 
Nav1.6 in the SoCx [25] might be suitable targets in AE genetic 
models. Relevant for this is that phenytoin, an antiepileptic drug 
known to enhance SWDs in absence patients and in the genetic 
models, reduces SWDs when administered in the cortical initiating 
zone [63]. HCN channels and their subtypes 1,2, and 4 expressed in 
cortex and thalamus appear to be involved in SWD occurrence in 
genetic models [64,65]. Yet, there are only a few selective pharma-
cological agents such as MEL57A and EC-18 for HCN1 and HCN4 
respectively that target the different subtypes [66]. However, they 
await being evaluated in the genetic models. A single preliminary 
study showed that the Ih blocker ORG 34167,which has a high af-
finity for the HCN1 receptor, suppressed SWDs in WAG/Rij rats. 
The drug prolonged also the duration of wakefulness characterized 
by a desynchronized EEG and passive behavior [67]. The cannabi-
noid system modulates SWDs, as was suggested by the use of 
R(+)WIN55212-2, a CB1 receptor agonist. R(+)WIN55212-2dose-
dependently reduced the incidence of SWDs in the first 3 h after 
injection, and this was followed by an increase in the mean SWD 
duration, suggesting a biphasic modulation of SWDs by this ago-
nist. Both effects were reversed or attenuated when the agonist was 
combined with the antagonist AM251 [68]. In agreement, the syn-
thetic CB1 receptor antagonist/inverse agonist SR141716 enhanced 
SWDs [69]. 
 Astrocyte-modulating approaches, in particular via the use of 
the glial modulating agent ONO-2506, have been shown to control-
non-convulsive forms of epilepsy in genetic mice model of absence 
epilepsy (Cacna1a(tm2Nobs/tm2Nobs), as it reduced both the num-
ber and mean duration of SWDs dose-dependently [70]. Similarly, 
gap junction blockers were suppressive, in line with the hypothesis 
that neurons of the reticular nucleus of the thalamus (RTN) contrib-
ute to synchronization necessary for the hyper synchrony of the 
thalamo-cortical network during SWD [71]. Adenosine might also 
play a role in AE after it was established that non-selective 
A1R/A2R antagonists reduce SWDs [72] and that the receptor den-
sity of excitatory A(2A)R was lower in 2 month (presymptomatic) 
WAG/Rij rats when compared toaged matched control rats. Accord-
ingly, A(2A)R stimulation ofcortico-thalamicbrain slices from the 
young WAG/Rij rats, with the agonist 2-[4-(-2-carboxyethyl)-
phenylamino]-5'-N-ethylcarboxamido-adenosine failed to modulate 
either cAMP formation, mitogen-activated protein kinase system, or 
K(+)-evoked glutamate release. In contrast, compared to the control 
animals, symptomatic WAG/Rij rats showed a significant increase 
in the expression of A(2A)R, receptor signaling and function. Ap-
plication ofthe 2AR antagonist SCH58261 reduced the number and 
mean duration of SWDs, regardless of whether the drug was admin-
istered in cortex, thalamus or systemically. It was suggested that 
SCH58261 is effective in preventing absence seizures by blocking 
the facilitatory A(2A)R activity, which may contribute to the trig-
gering/maintenance of SWD [73]. 
 The mechanism of action of LEVis based on the synaptic vesi-
cle protein named 2A (SV2A). This protein is ubiquitously ex-
pressed in the brain and SV2A knockout mice were shown to de-
velop a strong seizure phenotype. It was predicted that LEV might 
act on absences as well. When tested in either GAERS [74] or 
WAG/Rijrats [75] LEV was found effective in suppressing SWDs. 
Later, a similar suppressive effect was reported in AE patients [76] 
supporting the hypothesis that  SV2A ligands  have anti-absence 
effects. Finally, Neuropeptide Y has been found to be a modulator 
of SWDs: its presence on GABA-ergic cells of the RTN and the 
cerebral cortex makes it a suitable candidate. NPY signaling is-
through Y1, Y2, Y4, and Y5 G-protein-coupled receptors andacti-
vation of these receptors inhibits adenylate cyclase and decrease 
intracellular Ca2+ [77]. In GAERS, local application in the SoCx of 
NPY reduces SWDs, whereas its administration in the ventral basal 
complex of the thalamus increases them [78]. 
2.2. New T-Type Calcium Channel Blockers 
 The mechanism of action of the classical prototype of a T-type 
Ca2+ blocker, ETX, was revealed 30 years ago [79]. Coulter and 
coworkers showed that ETX blocks the T-type voltage-gated Ca2+ 
channel in thalamo-cortical neurons and reduced burst firing, al-
though other mechanisms have been found since then [80-84]. ETX 
appears particularly effectivewhen applied in the SoCx, as estab-
lished in GAERS, where it reduces the excitability of highly excit-
able subgranular pyramidal cortico-thalamic cells [11, 35, 85].In 
fact, ETX normalized the behaviour of these cells and by doing this, 
SWDs no longer occurred. This outcome suggests that a putative 
new drug for AE should be evaluated for its efficacy not only after 
systemic administration, but also for its action in SoCx.  Novel T-
type Ca2+ channel antagonists were tested in animal models [86] 
and in vivo assessment of two of them (Z941 and Z944), showed 
that both compounds suppressed incidence and mean duration of 
SWDs in GAERS more potently and by a mechanism distinct from 
that of ETX [87]. In the meantime, Z944 has entered clinical stage 
II, but as an analgesic. A new series of Ca2+ channel blockers 
withrelativelygood oral bioavailability and brain penetration across 
species, showed a robust reduction in the number and duration of 
SWDs with no cardiovascular effects in the WAG/Rijmodel [88]. It 
is not known whether these latter drugs will be further developed as 
anti-absence drugs. 
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 New anti-absence drugs might also target glutamatergic and/or 
GABA-ergic neurotransmission, the most relevant neurotransmit-
ters in the C-T-C network involved in the oscillations responsible 
for the highly characteristic SWDs. Here, we concentrate on 
mGluR, considering that the work in absence models has shed a 
different light on the existing literature regarding the role of gluta-
mate on epilepsy.   
2.3. MGlureceptors  
 The discovery of metabotropic glutamate receptors (mGluRs) at 
pre- and postsynaptic GABA-ergic and glutamatergic neurons and 
consequently their presence within the C-T-C circuit opened new 
vistas for the investigation of new anti-absence drugs [89]. Moreo-
ver, targeting mGluRs might be less toxic than targeting ionotropic 
GluRs. Allosteric modulators have been shown to be safer than 
orthosteric modulators and already have entered clinical trials for 
other neurological and psychiatric disorders [90]. Finally, drugs 
binding to mGluR do exert pro- or anti-epileptic effects in various 
seizure and epilepsy models, so the roles as putative antiepileptic 
drugs deserves to be explored [91]. 
 Based on amino acid sequences, pharmacologic profile, and G-
protein coupling profile, mGlu receptors are subdivided into three 
groups  with 8 subtypes [92]. Group I consists ofmGlu1 and mGlu5 
receptors, which are coupled to Gq proteins.  Activation of these 
receptorstriggers the hydrolysis ofpolyphosphoinositide and forma-
tion of inositol-1,4,5-trisphosphate and diacylglycerol. MGlu1 and 
mGlu5 receptors also control the activity of various types of Ca2+ 
and K+ channels [93]. Group II receptors (mGlu2 and mGlu3 re-
spectively), which are coupled to Gi/Go proteins, negatively modu-
late the activity of adenyl cyclase and voltage-sensitive Ca2+ chan-
nels (VSCCs). Group III consists of mGlu4, mGlu6, mGlu7, and 
mGlu8 receptors, which are also coupled to Gi/Go proteins. The 
availability of selective orthosteric and even more important selec-
tive positive and negative allosteric modulators (PAMs and NAMs) 
will give new opportunities to investigate compounds for their pos-
sible anti-absence action. Here the results of studies with the 
WAG/Rij model will be discussed.   
 Group I: The roles of group I mGlu receptors—both mGlu1 and 
mGlu5 were investigated. These receptors are mostly expressed in 
the peripheral portion of the postsynaptic density, where they cause 
excitatory responses and control synaptic plasticity [94]. The ex-
pression and signaling of mGlu1 receptors was reduced in the 
thalamus of WAG/Rij rats when compared to aged matched non-
epileptic control rats. The mGlu1 NAM, JNJ16259685 showed a 
dose-dependent increase in the number of SWDs, while the mGlu1 
PAM, RO0711401 decreased dose and time dependently the num-
ber of SWD. It is possible that the effects of this PAM on number 
and duration of SWDsin WAG/Rij rats are caused by hypo-function 
of mGlu1 receptors in the thalamus. We have proposed that this 
PAM should be further developed as an anti-absence drug in par-
ticular, although at forehand it is surprising that a drug known to 
increase glutamatergic neurotransmission reduces SWDs [94]. 
 WAG/Rij ratsshowed a decrease in both the mGlu5 receptor 
protein levels and receptor function in the thalamus when compared 
to age-matched non-epileptic ACI (Agouti-Copenhague Irish) rats. 
In contrast, the expression of mGlu5R was enhanced in the motor 
and SoCx without an accompanying change in mGlu5-receptor 
function [95]. The pharmacological studies showed that the selec-
tive mGlu1R PAM, VU0360172, significantly reduced SWDs, 
without affecting motor behavior. Importantly, the effects of this 
PAM were prevented by co-treatment with the selective antagonist 
MTEP. This may indicate that the PAM decreased SWDs by ampli-
fying the endogenous activation of mGlu5R.  Whether these phar-
macological effects are due to a hypo-functional thalamus as was 
found in WAG/Rij rats remains to be answered by testing the com-
pound in other genetic models that do not show this hypo-
functional thalamus.  
 Antiepileptic drugs have to be chronically administered and 
therefore it was subsequently investigated whether RO0711401 and 
VU0360172 develop tolerance [96]. WAG/Rij rats were injected 
twice daily for 10 consecutive days. Rats quickly (on the third day) 
developed tolerance to RO0711401. In contrast, VU0360172 kept 
its anti- absence activity (Fig. 1).  
 
 
Fig. (1). Effects of sub chronic (10 days, twice-daily s.c.) administration 
of Group I PAMS (RO0711401, 10 mg/kg and VU0360172, 3 mg/kg) and 
their respective vehicles. Tolerance developed for the anti-absence activity 
of RO0711401 at the 3rdday of treatment, VU0360172 seemed devoid of 
tolerance. A rechallenge with each of the two drugs was performed after 2 
days of withdrawal. The incidence of SWDs at 1 h after the morning injec-
tion is shown. Values are Mean ± S.E.M. P < 0.05 vs. the respective vehi-
cles. (adapted after [96]) 
 
 Group II. Only two studiesaddressed the role of Group II 
mGluR. Six-month-old symptomatic WAG/Rijrats showed an in-
creased expression of mGlu2/3 R’s in the ventrolateral regions of 
the SoCx, ventrobasal thalamus, and hippocampus, but not in RTN 
as assessed by immunohistochemistry and western blotting com-
pared to presymptomatic so young WAG/Rij and to non-epileptic 
control rats. In contrast, mGlu2/3 receptor signaling was reduced in 
the SoCx. It was proposed that ‘upregulation of these receptors in 
the SoCx might be involved in the pathogenesis of absence epi-
lepsy’. The orthosteric mGlu2/3 receptor agonist LY379268 dose-
dependently increased the number of SWDs during 3-7 h post-
treatment, whereas the orthosteric antagonist LY341495 dose-
dependent reduced its number [97]. However, studies in lh/lh mice 
with the same mGlu2/3 receptor agonist (LY379268) showed an 
opposite effect, i.e., a decrease in SWD incidence.Altogether, 
mGlu2/3 receptors appear to beinvolved in the generation of SWDs 
and an upregulation of these receptors in the SoCx might contribute 
to the pathogenesis of absence epilepsy [89]. 
 Group III. Very little has been done regarding receptors in this 
group; here we briefly mention what has been done with the mGlu4 
and mGlu8 receptors. MGlu8Rs are present at glutamatergic cor-
tico-thalamic synapses innervating RTNand TC neurons. In intact 
cortico-thalamic slices, group III mGluR activation by the selective 
orthosteric agonist l-AP4 suppressed evoked cortico-RTN re-
sponses. This was due to presynaptic suppression of glutamate re-
lease at the cortico-RT synapses via activation of autoreceptors. 
Indeed, selective activation of mGlu8R was sufficient to reduce 
cortico-RT synaptic release [98], and to dampen thalamic oscilla-
tions. Consequently, this action predicts that in vivo, SWD activity 
should be reducedby mGlu8R activation. The role of mGlu4R was 
investigated in WAG/Rij rats where its expression was enhanced in 
the RTN [99]. Electron microscopy and in situ hybridization data 
suggested that mGlu4 receptors in the RTN are localized on excita-
tory cortical afferents, confirming their role as autoreceptors. The 
presence of mGluR4 within RTN is therefore critical to GABAergic 
modulation of thalamo-cortical synchronization in normal and 
pathological oscillations (absence seizures). This and the work of 
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Kyuyoung and Huguenard [98] supports the hypothesis that activa-
tion of mGlu4 receptors may inhibit the release of glutamate in the 
RTN, reduces the role of the RTN in inhibiting of TC cells and also 
bursting. Therefore, PAMs of this group should reduce SWDs. In 
contrast with this hypothesis, we found that systemic injection of 
the selective mGlu4R PAM PHCCC, substantially enhanced the 
number of SWDs in WAG/Rij rats [100]. This wasin line with an 
increase in absence-like seizures in PTZ-treated mice, whereas 
PHCCC was inactive in mGlu4 receptor knockout mice; these ani-
mals were ‘intrinsically resistant to PTZ-induced absence seizures’ 
[91]. Selective stimulation and local injection studies with selective 
PAMs and NAMS in cortex and thalamus should clarify the role of 
group III mGluRs.  
3. ABSENCE EPILEPSY EPILEPTOGENESIS….. 
 The identification of a specific cortical region triggering SWDs 
in genetic rodent models of AE (see above), has recently instigated 
studies addressing the question whether the different characteristics 
of ictogenic neurons already exist at birth or progressively develop 
during brain maturation. This question is critical to design prophy-
lactic treatments capable of interrupting AE epileptogenesis. In 
rodent models of AE, the age of onset of the first SWDs varies from 
25 to 120 days postnatal [6]. In WAG/Rij rats the early develop-
mental changes in the focal zone have not been studied in such 
details. However, at 3.5 months of age, 85% of the WAG/Rij's have 
fully developed SWDs [14]. Two recent studies performed in 
GAERS rats and C3H/HeJ mice [13, 101] have shown that SWDs 
progressively mature during the first three weeks postnatal. Al-
though age windows are slightly different between these two 
strains, three similar stages clearly describe the course of epilepto-
genesis. The first stage is characterized by "oscillatory discharges", 
composed ofirregular narrow spikes and no apparent waves. In both 
models, these discharges are rare, have a frequency around 5 Hz 
without harmonics and are concomitant with behavioral arrest [13]. 
They first appear around P15 in GAERS and P5 in C3H/HeJ mice 
[101]. They are not found in age-matched non-epileptic controls, 
suggesting that they are specific to AE epileptogenesis and could 
represent a related rhythmic brain activity of AE [13,101]. The 
second stage is characterized by the occurrence of SWDs mixed 
with the oscillatory discharges. These mixed discharges are first 
observed around P25 in GAERS and P15 in C3H/HeJmice. In 
GAERS, the proportion of SWDs increases as a function of age, 
although they represent less than 50% of events at this stage. Acute 
injection of VPA suppressed both oscillations and SWDs at this 
stage, suggesting that both patterns are epileptiform and may reflect 
a maturational process of SWDs [13]. After P30 in both models, the 
discharges are composed of a greater proportion of SWDs and an 
increase in discharge frequency reaching 8-9 Hz [13, 101]. This age 
in these two rodent modelscorresponds well to the age at which AE 
is generally diagnosed in patients [102]. Using in vivo intracellular 
electrophysiological recordings of deep layer pyramidal neurons in 
adult rats, it was recently demonstrated [13] that this maturation of 
cortical discharges in GAERS is accompanied by a progressive 
increase in the intrinsic excitability and synaptic drive of cortical 
neurons. This should lead to an enhanced ability of SoCx networks 
to generate synchronized oscillations and paroxysmal episodes. 
These data suggest that SoCx neuronal network can maturate dif-
ferently in epileptic animals, leading to an abnormal functional and 
structural organization that facilitates neuronal hyperactivity and 
hypersynchronization.These changes occur in the rat at a period of 
cortical maturation which has been shown to be critical for the de-
velopment of functional networks in the SoCx [102, 103]. Molecu-
lar mechanisms involved in this functional development may there-
fore be key players in the pathophysiology of AE. Long-term 
changes in cortico-cortical, cortico-thalamic and subcortical net-
works in WAG/Rij and GAERS rats were also described even at 
rest and epileptogenesis is probably not restricted to the SoCx and 
its C-T-C network [29, 104, 105]. 
3.1. …..and Antiepileptogenesis 
 In an attempt to develop curative rather than symptomatic 
treatment ETX or VPA were given chronically in GAERS from the 
age of 5 days up to 25 days postnatal, i.e., during the critical period 
of epileptogenesis when SWDs are not fully matured(see above). 
However, such treatment hadno consequences on the recurrence of 
these seizures later on, when the animals were adults, nor change 
the efficacyof these drugs to suppress SWDs [13]. This suggests 
that, at least in this model, antiepileptic drugs are not effective in 
impairing epileptogenesis despite the fact that when acutely admin-
isteredthey cansuppress immature SWDs (see also [11]). In 
WAG/Rij, 4-month pharmacological treatment with ETX initiated 
immediately after weaning, i.e., before SWDs onset, suppressed 
seizures several weeks after treatment was stopped [106]: the age-
dependent increase in SWDswasdelayed or even prevented, sug-
gesting “antiepileptogenesis”. Theseinitial results were replicated 
several times [32, 107-109] and similar effects were also found in 
GAERS using the same protocol [110]. Initially, it was thought that 
the molecular changes due to epileptogenesis and antiepileptogene-
sis were restricted to the initiation site of SWDs [106]. Recently, it 
was shownthat changes in white matter, REM sleep, behaviour and 
network activityalso occur as a consequence of epileptogenesis and 
are “normalized” after a treatment leading to "antiepileptogenesis" 
[32, 107, 111]. However, it must be noted that a 2-month treatment 
with ETX either initiatedat weaning or 2 month later (instead of the 
4-month periodwhich was previously used), was not sufficient to 
reduce SWDs and modify behavior [32]. Russo and colleagues (for 
review see [56]) investigated the antiepileptogenic effects of differ-
ent compounds, not necessarily antiepileptic ones, onWAG/Rij rats 
with drug administration via drinking water from weaning to 5-6 
months of age. Some of these drugs have, when acutely adminis-
tered, a proabsence action (carbamazepine, CBZ and vigabatrin, 
VGA) or a weak antiabsence action (LTG), or no anti-absence ac-
tion (Perampanel, PER), in contrast to ETX [112]. Among the 
treatments with different antiepileptic drugs, LEV had mild effects, 
CBZ no effects and VGA had clear antiepileptogenic effects. The 
latter was surprising, since this compound and other GABA-
mimetic drugs increase SWDs in animal models and AE patients 
[113]. The antiepileptic drug PER, a selective noncompetitive 
AMPA-receptor antagonist, approved for e.g. adjunctive treatment 
of focal and primarily generalized tonic–clonic seizures, temporar-
ily suppressed SWDs after withdrawal [114]. These results show 
that mechanisms involved in antiepileptogenesis are different from 
mechanisms responsible for the acute SWD suppressing effects. 
The putative antiepileptogenic actions of psychoactive drugs were 
additionally explored. Both theselective serotonin reuptake blocker 
fluoxetine and the dual-acting serotonin-noradrenalin reuptake in-
hibitor duloxetinereduced SWDs, lower doses were not effective 
[56]. Three antipsychotic drugs haloperidol, risperidone and queti-
apine were not effective either, while three different statins, 
atorvastatin, simvastatin, and pravastatin, known for their neuropro-
tective and anti-inflammatory effects, decreased SWDs (mild to 
large effects). In addition, rapamycin (RAP) delayed the develop-
ment of SWDs in adult WAG/Rij rats, suggesting the involvement 
of the mTOR pathway [61], similar to what was found in other 
forms of epilepsy (e.g., lithium pilocarpine model of mesial tempo-
ral lobe epilepsy) in epileptogenesis [114]. As emphasized by these 
authors, chronic treatment only temporarily"suspended" the age-
dependent increase in SWD incidence. This implies that genuine 
and complete antiepileptogenesis has not been described yet in 
rodent models. This seems in contrast to what has been found in 
children with AE: in a retrospective clinical study, ETX was found 
to be associated with a high rate of complete remission [5]. Sponta-
neous remission and or a transition to more severeforms of genetic 
generalized epilepsy [51] were never reported in any genetic model 
of AE. This seems to be a real difference between the rodent mod-
els and clinical conditions. Such difference has to be taken into 
account when developing antiepileptogenesis treatments. In a dif-
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ferent approach WAG/Rij pups were treated from postnatal day 8 to 
21 with the antidepressant clomipramine twice daily [115]. This 
treatment decreased SWDs once the rats were 8-month old, while 
REM sleep was enhanced. This suggests that early interventions 
may have long lasting permanent effects on SWDs but also on sleep 
regulating mechanisms.  
4.1. Subcortical Stimulation 
 High-frequency stimulation of a number of deep brain struc-
tures has been proposed as a way to control epileptic seizures when 
other therapies (AED, surgical ablation, vagal nerve stimulation) 
fail or are not possible [116, 117]. Clinical trials of DBS in refrac-
tory epilepsy patients using continuous or intermittent stimulation 
protocols have yielded encouraging results [118, 119]. However, 
AE patients were never studied. High-frequency stimulation of the 
sub-thalamic nucleus was first shown to suppress SWDs in GAERS 
[120]. The idea to stimulate here came from studies on the role of 
the basal ganglia in the control of epileptic seizures [121, 122] . The 
optimal target was later found to be the substantia nigra reticulata, 
the main output station of the basal ganglia, and the optimal fre-
quency to interrupt SWDs was 60Hz [123]. However, these studies 
also revealed that open loop or ‘continuous stimulation of these 
structures rapidly lead to a lack of response, probably due to a re-
fractory period after each single stimulation’. Therefore,closed loop 
stimulation protocols, in which electrical stimulation will be trig-
gered by seizure onset   detected in real-time by the analyses of the 
ongoing EEG signals might be more appropriate [124-128], in 
particular when the seizure occurrence is high.  It is obvious that 
this is indeed the casein the genetic animal models and inunmedi-
cated AE patients. Closed loop stimulation presents three putative 
advantages for clinical use when compared to open loop continuous 
DBS: (i) less habituation and neural adaptation to stimulation; (ii) 
less behavioural or physiological unwanted-effects; (iii)more power 
saving and longer life for the batteries of the brain stimulators. An 
overview of the major stimulation studies in the genetic models and 
in rats with spontaneous SWDs is presented in Table I. 
 
Table I. Overview of electrical and optogenetic stimulation studies in the genetic absence models and in rats with absence seizures. 
Author (year)	  
Model or type of 
epilepsy	  
Type of stimulation	   Stimulation site	  
Frequency and dura-
tion of session	  
Outcome	  
Vercueil et al., 
1998	  
GAERS	  
5 sec bilateral high frequency stimula-
tion (130 Hz)	  
Subthalamic nucleus	  
At least 10 consecutive 
SWD	  
Disruption of SWD with intensities 
that do not induce motor responses	  
Feddersen et al., 
2007	  
GAERS	  
5 sec stimulation with various modes  
(referential vs bipolar; monophasic vs 
biphasic; unilateral vs bilateral) and 
parameters (pulse width, frequency) to 
obtainoptimal stimulation parameters	  
Substantia nigra pars 
reticulata	  
40 min	  
a) Optimal suppression of SWD with 
least side effects and lowest intensity: 
bilateral, bipolar, monophasic 60 Hz	  
b) 50% of non-interrupted SWD 
occurred shortly following a former 
interrupted SWD suggesting a refrac-
tory period	  
Liang et al., 2010	  
Liang et al., 2011	  
Long-Evans rats with 
generalized absence 
seizures	  
Closed-loop stimulation by automated 
BCI system, single pulse train of 
800Hz, 30-40µA and 0.5 sec pulse 
train duration	  
Zona incerta	  
2 h during light phase 
and	  
2 h during dark phase	  
90% of SWD disrupted by stimulation, 
detection delay time less than .6 sec	  
Saillet et al., 2013	   GAERS	  
a) Closed-loop bilateral, 2 sec, mono-
phasic, 60 Hz with different minimal 
inter stimulation intervals (ISI) to 
determine length of refractory period	  
b) Closed-loop, bilateral, 2 sec mono-
phasic, 60 Hz stimulation,  ISI 60 sec	  
Substantia nigra pars 
reticulata	  
a) 1 h	  
b) 5 h and 24 h	  
 	  
a) ISI of 60sec revealed highest 
antiepileptic efficacy	  
b) 99% of SWD disrupted by stimula-
tion, but increase in SWD number in 
5h session;	  
72 % of SWD disrupted by stimulation 
and decrease in SWD number in 24h 
session	  
Lüttjohann & van 
Luijtelaar, 2013	  
WAG/Rij	  
Repeated (closed-loop), unilateral, 130 






89% of SWD disrupted by stimulation, 
no increase or decrease in SWD 
number	  
 	  
Blik, 2015	   WAG/Rij	  
Unilateral, closed (at threshold inten-
sity) 1 sec monophasic pulse train; 
open loop (continuous at 50-70% of 





Closed-loop interrupted but elevated 
number of SWD and fragmented bouts 
of wakefulness. Open-loop stimulation 
at 70% threshold reduced number of 
SWD by 40% and raised active 
wakefulness and decreased slow-wave 
and REM sleep	  
 
(Table 1) Contd.... 
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Author (year)	  
Model or type of 
epilepsy	  
Type of stimulation	   Stimulation site	  
Frequency and dura-
tion of session	  
Outcome	  
van Heukelum et 
al., 2016	  
WAG/Rij	  
Closed-loop, unilateral, 130 Hz, 
1 sec	  
Somatosensory cortex	   24 h	  
91% of SWD disrupted by stimulation, 
decrease in SWD number during 
stimulation session and some hours of 
the post-stimulation recording session	  
Maximenko et al., 
2017	  
WAG/Rij	  
Closed-loop, unilateral, 130 Hz 
triggered by SWD precursors, 1 
sec	  
Somatosensory cortex	   1 h	  
72% reduction of SWD time based on 
combination of SWD prediction - 
prevention and SWD detection - 
disruption	  
Optogenetic Stimulation	  




stimulation using ChR2 either 
unilateral or bilateral	  
Cerebellar nuclei	   Not reported	  
Unilateral: 91.8% of disrupted SWD,	  
bilateral:  93.4% of disrupted SWD	  
Sorokin et al., 2017	   WAG/Rij	  
Closed-loop optogenetic 
stimulation using stable step 
function opsins	  
Ventral Posterior- Medial 
thalamic nucleus	  
20 - 60 min	  
Disruption of ongoing SWD, percent-
age / success rate not reported	  
Noninvasive Stimulation	  
Berényi et al., 2012	  




electrical stimulation (TES), 
Spike triggered stimulation by 
50-ms Gaussian waveform. 
Delay between spike and 
stimulus onset 0, 10 or 40 ms. 
Intensity: max 4-5 V.	  
Bilateral strip electrodes with 
same polarity above barrel 
cortex and one above anterior 
midline with opposite polarity.  
TES applied either between left 
and right or between bitemporal 
electrodes against frontal 
midline (whatever worked best)	  
Multiple (5-24) 10 min 
sham and TES sessions 
while the rat was sitting 
still in his home cage	  
>60% decrease time spent in SWD due 
to shorter mean duration; No rebound 
or long-term compensatory increase of 
their probability of occurrence. Ampli-
tude of the spike was	  
 	  
Zobeiri & van 
Luijtelaar, 2013 	  
WAG/Rij 	  
Open loop Transcranial anodal 
and cathodal direct current 
stimulation (tDCs), Exp I and 
II: 100 µA; Exp III: 150 µA 	  
Two stimulation electrodes 
(either anodes or cathodes) 
bilaterally on skull above the 
epileptic foci of the somatosen-
sory cortices, reference elec-
trode on frontal cortex	  
Exp I: 4 series of 15 min 
counterbalanced catho-
dal and anodal stimula-
tion interstimulation 
interval (ISI) 1 h 45 
min;	  
Exp II and III: 4 series 
of 15 min cathodal 
stimulation, ISI 1 h 45 
min	  
Exp I: Anodal stimulation tended to 
increase, cathodal to decrease number 
SWD.	  
Exp II & III: reduction in number 
SWD during stimulation and increase 
(II) or decrease (III) in mean duration 
of SWD during ISI	  




4 series of 15 or 30 minutes of 
cathodal transcranial l direct 
current stimulation (ctDCs)	  
On skull above left and right 
focal zone in somatosensory 
cortex, reference electrode on 
animal’s chest	  
intensity 150 µA, 	  
ISI 1 h 45 min or 1 h 30 
min.	  
Reduction in number and mean 
duration of SWD on stimulation day 
with both protocols.	  
30-min protocol reduced number and 
mean duration on post stimulation day.	  
Godlevsky et al., 
2006	  
WAG/Rij	  
1 series of 3 transcranial mag-
netic stimulation (TMS)	  
Motor cortex	  
1.5 sec (2 Hz), at 
threshold intensity	  
Non-sign reduction in SWD time for 
30 min after TMS	  
 
 When the anti-epileptic efficacy of automated responsive DBS 
(rDBS) of the substantia nigra reticulata was examined in freely 
moving GAERS for periods of up to 24 hours using an online SWD 
detection algorithm based on permutation entropy [129], 100% of 
sensibility of the seizure detection algorithm was obtained [130]. 
Seizure detection was excellent for short-term recordings, (up to 
99%), whereas for long-term recordings (24- h) it dropped to 72%, 
probably due to the increase in EEG components resembling SWDs 
(e.g. sleep spindles, feeding and grooming artifacts). At other peri-
ods SWDs occurred more frequently in clusters and were refrac-
tory. Despite these to-be-solved issues, the anti-epileptic efficacy of 
this way of stimulation was stable over therecording time [130]. 
Closed-loop high-frequency stimulation (130 Hz) of the thalamic 
Ventro-Posterior-Medial nucleus (VPM) in freely moving 
WAG/Rij rats also disrupted ongoing SWDs in about 89% of cases. 
By contrast, open loop low frequency stimulation (1 sec pulse-
trains of 8 Hz) induced SWD-like afterdischarges while the same 
stimulation in the anterior thalamic nucleus, i.e., outside of the 
SWD-relevant brain network, only rarely induced an afterdischarge. 
The rhythmic activation of the VPM by low frequency stimulation, 
might provide a ‘trigger input’ to the cortical focus, via the direct 
excitatory projections of the VPM to the SoCx [131]. In contrast, 
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high frequency stimulation of the VPM might have a desynchroniz-
ing effect on the network, hampering sustainment of SWDs, in line 
with outcomes of previous studies in GAERS [132]. Closed-loop 
100 Hz (1 sec trains) stimulation of the tuberomamillary nucleusin 
the brain stem in WAG/Rij rats also aborted SWDs but elevated the 
number of SWDs and fragmented bouts of wakefulness in a 3 hr 
recording session [133]. Open-loop stimulation at SWD interrup-
tion intensity of 70% reduced the number of SWDs by 40% and 
raised active wakefulness and decreased slow-wave and REM sleep 
[133].  
4.2. Cortical Stimulation  
 The effects of 24hrDBS in the cortical focal zone on SWDs and 
behaviour were investigated in WAG/Rij rats [134]. The authors 
delivered short (1 sec) DBS trains of 130Hz in the deep layers of 
the SoCxusing a previously validated SWD detection algorithm 
while rats of the yoked control group were stimulated at the same 
time. In addition to a robust disruption of ongoing SWDs by the 
stimulus train, the authors observed a reduction in the number of 
SWDslasting severalhours after the end of the stimulation, see Fig 
2. This suggests that DBS stimulation may induce local neuro-
modulatory effects such as long-term depression or long-term po-
tentiation in the reciprocally connected thalamus (VPM), known to 
display an increased tonic inhibition in absence epileptic rats [135]. 
Interestingly, induction of these neuromodulatory effects critically 
depended on the timing of stimulation: in other words,  reduction in 
the number of SWDs  during the 24 hr following stimulation was 
only seen in the group in which DBS was immediately applied upon 
SWD onset but not in the yoked control group [134]. 
 Open loop stimulation at a single cortical site with a single 
pulse or 2 pulses separated 400 msec or 8 Hz stimulation in the 
thalamus may elicit afterdischarges, not different from SWDs [31, 
136].  
4.3. A brain-Computer Interface for SWD Prevention? 
 Based on the above cited studies, the feasibility of SWD pre-
vention seems now within reach. It is based on a ‘closed-loop pre-
cursor detection – stimulation brain computer interface’. The on-
line detection of SWD precursors on the EEG would allow to 
stimulate a brain region and prevent the occurrence of SWDs, simi-
larly as was done in the SWD abortion studies. Recently, it was 
shown that SWDs are preceded by the simultaneous occurrence of 
delta and theta activity in cortex and thalamus [7], while network 
analyses showed that communication between these two brain 
structures already changed preictally [21, 30, 131, 137]. This led 
the group of Hramov et al to develop an algorithm for the detection 
of SWD precursors and to implement it in a closed-loop brain-
computer interface(BCI) system, applying cortical high frequency 
electrical stimulation as soon as a precursor was detected [138, 
139]. 
 The algorithm predicted correctly 88% of SWDs, albeit with a 
large number of false positives, mainly during light slow-wave 
sleep, see Fig. 3. Adaptation of the algorithm to reduce the number 
of false detections had a trade-off insensitivity. Although sensitivity 
and specificity of this on-line SWD prediction system remains to be 
improved, it opens a new line of research, searching for optimal 
‘responsive’ precursor detection and stimulation protocols for sei-
zure prevention. Most relevant is that the studiesdescribed so far 
provide a methodological approach for experiments with longer 
lasting sessions, making it necessary to validate the stability of DBS 
over several days. The current development of new programmable 
implantable devices should make it more feasible to assess chronic 
effects of DBS in epilepsy and in the genetic AE models. These 
models will be valuable preclinical tools to further develop and 
implement these protocols that could be then subsequently applied 
to other models, e.g in models of drug-resistant epilepsies.  
4.4. Optogenetic Stimulation 
 Optogenetic, a very recent form of brain stimulation has been 
applied in different models of neurological diseases. Specific cell 
types and neuronal populations are transfected with light-sensitive 
opsins, which either inhibit or activate the transfected neurons upon 
light stimulation delivered to the brain structure via an optical fiber 
[140]. As for electrical stimulation, optogenetic stimulation can be 
 
Fig. (2). Effect of timing of stimulation. WAG/Rij rats were stimulated in pairs: one animal received closed-loop stimulation (a 1 sec pulse train of 130Hz, 
0.4sec pulse duration) whenever a SWD was present in its EEG; the coupled partner received the same type of stimulation (1 sec pulse train of 130Hz, 0.4sec 
pulse duration) at the same moment in time, independent of whether it showed a SWD or not (yoked stimulation). Comparison of SWD number is done be-
tween a 24 hours baseline session, the 24 hours stimulation session and a 24 hours post-stimulation session. Data are average SWD numbers of 7 rats per 
group. Note that each of the 24 hour sessions is divided into 6 time-blocks: time-block 1: 1230 - 1630, time-block 2: 1630 - 2030, time-block 3: 2030 - 0030, time-
block 4: 0030 - 0430, time-block 5: 0430 - 830, time-block 6: 830 - 1230. Next to an overall decrease in SWD number during the stimulation as compared to the 
baseline session seen for both groups, a significant decrease in SWD number (as compared to baseline) was found for the closed-loop group during the last two 
time-blocks of the post-stimulation session (indicated by an *). A + indicates a significant change in SWD number in this time-block compared to the same 
time block during the stimulation day (adapted after [134]).   
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either applied using intermittent (‘open-loop’) or responsive 
(‘closed-loop’) protocols. Optogeneticsis preferably used to disen-
tangle the contribution of a particular element of a brain network in 
seizure generation and termination. Kros and colleagues (2015) 
demonstrated that ‘optogenetic closed-loop’ activation of neurons 
of the cerebellar nuclei successfully disrupt ongoing SWDs in two 
mouse models of absence epilepsy (the mutant tottering mouse and 
the C3H-HeJ mouse), while the same stimulation applied to the 
cerebellar cortex was inefficient. Since the cerebellar nuclei send 
excitatory projections to the thalamus, the authors argued that acti-
vation of the remote cerebellar nuclei has changed the balance of 
excitation and inhibition in the thalamic relay nuclei and alsothe 
bursting firing mode to the tonic one, therefore SWDs were aborted 
[141]. This balance is usually created by an interplay between the 
direct cortical projectionsproviding excitation to thalamic relay and 
RTN cells and inhibition provided by the RTN to relay cells [141, 
142]. Sorokin et al. transfected thalamo-cortical neurons of the 
VPM with stable step function opsins. With this technique, they 
were able to switch phasic bursting of these neurons, as observed 
during SWDs, into a tonic firing pattern upon light stimulation. 
Implemented in a closed-loop BCI, this stimulation disrupted ongo-
ing SWDs in freely moving WAG/Rij rats [142]. Interestingly, 
triggering burst firingin these relay neurons by optogenetic stimula-
tion was sufficient to generate SWDs in these epileptic rats, sug-
gesting that excitatory cortical input to the thalamus might  contrib-
ute to the occurrence of SWDs.  
4.5. Non-invasive Stimulation 
 Closed-loop stimulation systems have also been applied in less 
invasive stimulation settings. Berenyi et al., [144] provided closed-
loop transcranial 50msec Gaussian waveforms to Long-Evans rats 
with SWDs via bilateral plate electrodes with 5 contact points in the 
anterior-posterior axis placed on the skull above the barrel cortex or 
between the barrel and frontal cortex, whatever worked the best. 
Stimulation was triggered by a real-time spike detection method;  it 
shortened SWDs by quenching the ongoing rhythm through wide-
spread cortical stimulation [143]. The use of these particular plate 
electrodes over the left and rignt barrel cortexdiffuses the applied 
currents over a large cortical area. This mightexplain why in this 
case single pulses interrupted SWDs.  
 Transcranial direct current stimulation (tDCS) is a noninvasive 
brain stimulation technique with potential clinical benefits fora 
range of neurological disorders including Parkinson’s disease, ma-
jor depression, Alzheimer’s disease and also some types of focal 
epilepsies with a cortical origin [144-146]. A clinical trial reported 
that a single 20-min session of tDCS (1mA) over the epileptogenic 
focus of patients with cortical dysplasia reduced the discharge fre-
quency, with a trend towards a decrease in the number of clinical 
seizures [147]. A weak constant electrical current, applied through 
scalp electrodes, can modulate the underlying cortical neural activ-
ity by either affecting the neuronal firing rate and pattern or chang-
ing the synaptic release probability [148]. The two forms of tDCS, 
anodal (atDCS) and cathodal tDCS (ctDCS) refer respectively to 
the application of positive and negative current to the target area. In 
general, atDCS results in an overall increase in cortical excitability, 
whereas ctDCS induces cortical inhibition. The latter is of particu-
lar relevance in the treatment of focal types of epilepsy asthese 
types of epilepsy are often considered to result from too much exci-
tation and/or too little inhibition [149,150].Using bilateral tDCS 
stimulation over the SoCx in WAG/Rij with a third electrode on 
frontal cortex serving as a reference (Fig4.A), allowing current flow 
over a large part of the cortex, Zobeiri and van Luijtelaar (2013) 
[151] showed that only ctDCSreduced the number of SWDs (Fig. 
4C) and tended to decrease the mean duration. The antiepileptic 
effect of ctDCS was intensity-dependent from 100 to 150µA. Spec-
tral analyses of the EEG during the 15-min stimulation at 150µA-
stimulation showed an increase in power of delta (1-4 Hz) and sub-
delta (0.5-1 Hz) bands, suggesting that ctDCS hyperpolarized the 
cell membranes in the stimulated area. 150µA ctDCS had also, 
albeit short, lasting after effects on mean duration of SWDs over 
the 1-hour 45-minute inter-stimulation interval. 
 The efficacy of tDCS can be increased by reducing the elec-
trode size or using an extracephalic reference electrode [152] and 
this might have consequences for the duration of the desired effects. 
We tried to increase the focality of ctDCS above the focal cortical 
zone in WAG/Rij rats by replacing the frontal electrode by a refer-
ence chest electrode (Fig.4B). In this case,30-min stimulation 
yielded a larger effect than 15-min and the antiepileptic effects of 
30-min outlasted the stimulation period (Fig.4D). Number and 
mean duration of SWDs tended to be lower than baseline values on 
the day following stimulation suggesting long-term effects. How-
ever, these long-term effects were not seen when stimulationwas 
restricted to 4 x 15 min.    
 Antiepileptic effects of ctDCS and not atDCS were reported in 
other animal models for different types of epilepsy, such as  cortical 
ramp-stimulation, a model for acute focal seizures [153] and PTZ- 
induced generalized tonic-clonic seizures in rats [154], as well as in 
the pilocarpine status epilepticus model [155], where neuroprotec-
tive effects for ctDCS were found. It has been proposed that if the 
second stimulation session takes place during the aftereffects of the 
first session, the antiepileptic effect of ctDCS is prolonged [156]. 
Intensity and duration of stimulation, as well as  position and size 
ofactive and reference electrodesare important  parameters which 
define the efficacy of tDCS [152, 157]. Finally, the effects of re-
petitive stimulations need to be investigated in AEmodels, as was 
done in patients with mesial temporal lope epilepsy [146]. It is im-
portant to emphasize that there are also safety restrictions to DC 
stimulation and therefore strategies to prolong or increase the inten-







Fig. (3) Performance of SWD prediction algorithm. Percentage of predicted (88%) and detected (12%) SWDs within 4 hours recording of the six WAG/Rij 
rats (left panel). No SWD remained undetected; Number of false positives across different states of alertness (right panel). Note, for each rat and each state of 
alertness, 5 segments of 50 seconds duration were randomly selected in each recording for quantification of the false alarm rate (adapted after [139]).  
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 The results of these studies propose that ctDCS canbe used as a 
possible therapeutic non-invasive brain stimulation method in epi-
lepsy, including AE. However, evidence that the effects of ctDCS 
outlast the duration of the stimulation period in epilepsy patients or 
in experimental epilepsy animal studies is scarce. Although the 
short lasting effects of ctDCS seem to be directly dependent on the 
polarization of the neuronal cell membrane, the after effects appear 
mostly associated with more complexcellular and network mecha-
nisms including “gene activation/regulation, de novo protein ex-
pression, morphological changes, changes in intrinsic firing prop-
erties and modified network properties resulting from changed 
inhibition, homeostatic processes and glial function and genetic 
variations in neuronal network functioning” [158, 159]. Early 
pharmacological studies suggest that after effects of ctDCS may 
result from persistent modification of synaptic efficacy similar to 
those underlying long-term depression as well as a reduction in 
glutamate and GABA [160-162]. Future tDCS research should fo-
cus on optimization of stimulation parameters and factors such 
asstimulation intensity, duration, repetition rate, repetition interval 
and electrode montage including the location of the reference, as 
well as safety issues. 
 A single study described the effects of transcranial magnetic 
stimulation (TMS) in the genetic models [163]. TMS (0.5 Hz, 3 
impulses) was applied in WAG/Rij rats at threshold intensity to the 
motor cortex and its effects on SWDs were compared with a sham 
stimulation group. TMS reduced the number of SWDs by 31.4% in 
comparison with the sham group in the first 30 min from the mo-
ment of cessation of stimulation. The number of SWDs returned to 
pre-stimulation level after 90-150 minutes. It is obvious that also 
TMS could be an intervention option, however, more experiments 
need to be done before this can be considered for clinical trials.  
5. RADIOSURGERY USING SYNCHROTRON-
GENERATED MICROBEAMS 
 Traditional bilateral resective surgery of the SoCx in acutely 
prepared WAG/Rij rats was shown to reduce all SWDs [164]. 
However, this drastic option will not be easily translated, perhaps 
only in children with a frontal type of absence epilepsy with large 
cognitive detoriations. Radiosurgery may represents a promising 
therapeutical alternative and modern radiosurgical devices such as 
Gamma Knife® and Cyberknife® [165]  have already yielded en-
couraging results in different types of epilepsies [166]. However,the 
radiosensitivity of the healthy tissue arround the epileptic foci is the 
limitation factor in this type of treatment [167]. In contrast, ‘low-
energy photons generated by 3rd generation synchrotron sources 
allows the deposition of extremely steep lateral dose fall-off and 
provides sufficient precision to perform experimental studies in 
animal models of epilepsy’ [168]. Recently, researchers at the Euro-
 
Fig. (4). Effects of transcranial direct current stimulation (tDCS) on absence epilepsy. A Simplified scheme of tDCS montage on the rat skull, indicating 
the location of two active bilateral electrodes (in light grey) on the excitable zones of the somatosensory cortices and a reference electrode on the frontal cor-
tex.  B. Simplified scheme of tDCS montage on the rat skull, indicating the location of two bilateral active electrodes (in light grey) on the excitable zones and 
the reference electrode (in black) on the chest. This montage was used to increase the focality of the stimulation on the epileptogenic zones of the somatosen-
sory cortices. C. Bar graph indicating theintensity-dependent antiepileptic effects of repeated cathodal tDCS (ctDCS) on number of spike-wave discharges 
(SWDs) in WAG/Rij rats using the tDCS electrode montage shown in A. Each rat received 4 series of 15-minute cathodal stimulation with the intensity of 
either 100 or 150 µA and interstimulation interval of one hour 45 minutes while LFP was recorded and behavior was monitored. D. Left panel illustrating the 
effects of 4 times 30 min repeated ctDCS 150 µA spread over an eight-hour period on number of SWDs, using the tDCS electrode montage shown in B. Note 
the significant long-lasting reduction in the number of SWDs one day after ctDCS as was established in a 8 hr recording session. D. right panel indicates the 
significant reduction in the total duration of SWDs both at stimulation day and the day after stimulation cessation. 
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European Synchrotron Radiation Facility (ESRF) in Grenoble used 
spatial fractionation of ionizing radiation in the microscopic range. 
It allowed to produce ‘sharply defined beam edges deep in the tis-
sues with a high dose rate and to investigate the effects of arrays of 
25-75 µm-wide beam slices spaced 50–200 µm on centre’ [169]. 
Surprisingly, using this protocol, animals tolerate doses of hun-
dreds, or even thousands of gray of such microbeams delivered to 
their brains [169], with tissue damage confined to the microbeams 
tracks [170].  
 ‘By rotating the brain around a center of rotation using a go-
niometer, it is possible to precisely "interlace" microbeams to de-
posit a high homogeneous radiation dose into discrete brain regions, 
with no extension on neighboring tissue [171]. The possibility of 
accurate targetting of the epileptic zone, as well as preservation of 
surrounding tissues, makes this procedure clinically attractive for 
many types of pathologies which require destruction, inactivation 
and/or disconnection of small brain regions, even close to eloquent 
or vital structures. The efficacy of this technique was first testedin 
rodent brain tumor treatment and later on it was also used  for other 
brain diseases such as epilepsies.  
 The GAERS model with its well described ictogenic neurons in 
the SoCx was used for a proof of principle [38], also because there 
is no gross cell loss and/or sclerosis in this model therefore avoid-
ing confounding factors in therapy evaluation. Of note, it is obvious 
that such therapy will never beapplied to AE patients or only in 
cases of serious deteriorating types of epilepsy. The group of An-
toine Depaulis targeted brain regions using spatially fractionated 
beams into an array of parallel microbeams [38] to achieve micro-
transections aimed at “disconnecting” tissue slices from each other, 
and to avoid spreading of epileptic activity over the cortex. The 
correct targeting of the SoCx was verified in each animal by T1-
weighed MRI within the two weeks that followed irradiation, con-
firming the precision of radiation targeting and insignificant altera-
tions in the surrounding tissues. Histopathological verification of 
the radiated tissue revealed minor structural tissue damage in a 
period of 2 monthsafterirradiation. The microbeam tracks were 
clearly visible in the SoCxon histological brain sections, as thin 
clear stripes alternating with darker, non-irradiated tissue. Radiation 
effects were also confirmed on immuno-labeled slices with differ-
ent neuronal markers, astrocytes, basal lamina, angiogenesis and 
glucose transporter. Although the SoCx was targeted bilaterally, no 
significant behavioral alterations were measured with Rotarod® 
and open-field tests 2 weeks post-irradiation. These control studies 
confirmed that this type of synchrotron-generated microbeams have 
limited deleterious effects on brain tissue and motor or cognitive 
behaviors [38]. 
 During the 4 months that followed irradiation, EEG recordings 
showed that microbeam irradiation suppressed SWDs when the 
whole SoCx was irradiated. ‘While non-irradiated cortical and tha-
lamic regions could still produce epileptic discharges, the irradiated 
volume became isolated from the pathological activity. In contrast, 
irradiation of the motor cortex or ventrobasal thalamus did not sig-
nificantly suppress SWDs’ [38]. The mechanisms of the functional 
exclusion of the SoCxwas further investigated by individually re-
cording irradiated neurons two months after irradiation using in 
vivo intracellular electrophysiological recordings, as described be-
fore [19]. ‘This approach revealed that the irradiated pyramidal 
neurons were strongly hyperpolarized, displayed a decreased excit-
ability and a reduction of spontaneous synaptic activities’ [38]. 
‘These functional alterations may explain the suppression of parox-
ysmal oscillations within irradiated cortical networks. This work 
provided the first post-irradiation electrophysiological recordings of 
individual neurons. As such, these recordings are a preliminary and 
critical step towards understanding how ionizing radiation energy 
delivery impacts neuronal physiology and pathophysiology. Indeed, 
our data should provide clues on how radiation dose should be de-
livered for targeting epileptic neuronal networks’. This approach 
also allows to decipher the role of horizontal connection with the 
SoCx in the synchronization of neurons involved during SWDs. 
6. NEUROFEEDBACK  
 Neurofeedback training is a non-invasive therapeutical ap-
proach and positive effects were reported in drug-refractory patients 
including some with AE. Extended training involved feedback and 
instrumental conditioning aiming to reduce the slow cortical poten-
tials (SCP), an assumed marker of excitability. Most relevant is that 
some of thepatients with epilepsy were able to achieve a reduction 
in seizure occurrence [172]. The sample size and the heterogeneity 
of the studied population hampered clear conclusions. Indeed, not 
all patients could learn to reduce their SCP and there were few fol-
low-up studies. Based on the neuro-feedback studies on cats, it is 
more suitable to enhance the sensory motor rhythms (SMR, 12-
15Hz) at central locations, sincethese regions areneurophysiologi-
cally associated with alert and motionless processes [173]. SMR 
production appears to reduce in patients with epilepsy, while theta 
(4–9 Hz) oscillations are increasedwhen compared withnormal 
subjects [173,174]. However, methodological issues (heterogeneity 
of patient population, small number of subjects, proper pre-training 
EEG controls, proper control groups, motivation of the subjects, 
placebo effects) hamper clear conclusions about the effectiveness of 
neuro-feedback training. Animal studies using genetic models of 
AE, might indicate whether SWDs are under operant control, a 
precondition for effective neuro-feedback training. Osterhagen et al. 
reinforced SWDs by the presentation of a sucrose pellet during 10 
sessions in WAG/Rij rats [175]. A BCI system controlled the train-
ing phase of the experiment, during which the occurrence of SWDs 
was immediately followed by the presentation of reward. Reinforc-
ing SWDs decreased SWDs occurrence during training, the oppo-
site of what was trained and aimed at. Moreover, it was also found 
that this decrease in SWDs during the training phase were not per-
sistent in the post-training sessions. Because behavioural states are 
knownto heavily modulate the occurrence of SWDs (SWDs do not 
occur during arousal but preferentially occur during passive wake-
fulness, drowsiness and light slow wave sleep), it was proposed that 
increased arousal, experimentally created by the availability and 
presentation of the palatable foot pallets consequently resulted in 
fewer SWDs. Additional control tests supported this hypothesis and 
therefore precluded a clear answer whether SWDs can really be-
come under operant control, the latter is a sine qua non condition 
for successful neurofeedback training. Interestingly, the fact that 
SWDs are preceded by precursor activity might offer the possibility 
to use neurofeedback training to prevent the occurrence of this pre-
cursor activity, an option to control SWDs. 
CONCLUDING REMARKS 
 Despite the introduction of LTG, ZNS and LEV, treatment of 
AE has not been much renewed for the last 50 years. The first gen-
eration AEDs, ETX and VPA are still the drugs of choice. Interest-
ingly, which of the two drugs might work the best appears now 
predictable. We propose that the main reason for the high efficacy 
of ETX has been elucidated in the genetic models: it blocks the 
excitable cells in the initiating cortical regions and additional sei-
zure control isachieved by its action on thalamic cells, its action on 
Na+ currents and on cortical GABA.  Another important contribu-
tion for the success of ETX is that it may have antiepileptogenic 
effects in children with absence epilepsy and in the genetic models, 
although this is still debated. The acute reduction of absence sei-
zures by ETX may contribute to the long term outcomes after 
chronic treatment (antiepileptogenesis) and we propose that the 
combined actions of ETX can be summarized as that “seizure sup-
pression begets seizure remission”. The reason why VPA is also 
rather effective as an anti absence agent is less clear; its mode of 
action is plural. It is primarily a voltage-dependent Na+ channel 
blocker. Blockage of these channels in the SoCx with phenytoin 
reduces SWDs [63]; whereas blocking Na+ channels in the thalamus 
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enhances SWDs, as was demonstrated with CBZ [176]. Therefore, 
blocking voltage dependent Na+ channels alone cannot explain the 
efficacy of VPA. Interestingly, the action of CBZ in the thalamus 
was antagonized by the GABAa antagonist bicuculline, suggesting 
that the SWD enhancing effects of CBZ could be ascribed to 
GABA mimetic effects in the thalamus. Indeed, increased thalamic 
GABA-ergic inhibition is a key factor in the genetic models [135,  
177]. Other mechanisms, such as blockade of T-type Ca2+channels, 
must be responsible for the favourable action of VPA in absence 
epilepsy. Local injection studies might be helpful to elucidate 
where VPA is acting. For clinical practice it is important that the 
antiepileptogenic effects of the Na+ channel blockers, as found with 
CBZ, are absent in the genetic models [56] and that antiepilepto-
genesis effects in children with AE are much weaker upon VPA 
treatment when compared to ETX one [5]. The lower efficacy of 
LTG, another Na+ channel blocker, was predicted by van Rijn et al., 
[178]: these authors found a small reduction in SWDs after the 
highest dose only. The working mechanism of LTG precludes it 
from a good efficacy considering supposed opposite actions on 
SWDs in cortex and thalamus, as can be assumed based on the ac-
tion of other Na+ channel blockers such as CBZ and phenytoin.  
 In the last 40 years, new therapeutical approaches have mainly 
targeted drug-resistant epilepsies with focal origins, not AE pa-
tients. However, several approaches can be considered in the future 
that could help patients with AE, in particular when seizures persist 
during adulthood and/or when they are less benign. 
 Although AE is classified as a generalized form of epilepsy, 
recent data in animal models and AE patients suggest thatit shares 
with focal epilepsies the existence of a specific brain region that 
generate seizures, although the initiation zone is bilateral in AE. 
This implies that innovative therapeutical approaches can be de-
signed to target and reduce the excitability of cells in the seizure 
generating zone. Targeting cortico-thalamo-cortical and/or thalamo-
thalamic network activity with more specific drugs remains an effi-
cient option. In particular, recent rodent studies suggest that chronic 
drug treatment could modify or delay AE epileptogenesis. In this 
respect, AE constitutes aprototypic form of idiopathic/generalized 
epilepsy that could help design innovative curative treatment during 
brain development. Indeed, although many of the experimental 
methods will never be used in AE patients, except in extremely 
difficult to treat cases, the experiments reported here might be help-
ful in designing experiments and procedures for less benign forms 
of epilepsy.  
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